Clear cell carcinoma of the ovary: A review of the literature

Gynecologic Oncology

Volumn 126, Issue 3, 2012, Pages 481-490

  Del Carmen, Marcela G ^a   Birrer, Michael ^a   Schorge, John O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Clear cell; Ovarian; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IRINOTECAN; MITOMYCIN C; NEDAPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA; PHOSPHOPROTEIN PHOSPHATASE 2; PLATINUM; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; EARLY CANCER; GENE EXPRESSION PROFILING; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84864396450     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.021     Document Type: Review

References (137)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. B.A. Goff, R. Sainz de la Cuesta, H.G. Muntz, D. Fleischhacker, M. Ek, and L.W. Rice Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease Gynecol Oncol 60 1996 412 417 (Pubitemid 26077628)
3. M.J. Piccard, K. Bertelsen, K. Jame, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708 (Pubitemid 30365530)
4. H.J. Mackay, M.F. Brady, A.M. Oza, A. Reuss, E. Pujade-Lauraine, and A.M. Swart Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer Int J Gynecol Cancer 20 2010 945 952
5. M. Kobel, S.E. Kalloger, D.G. Huntsman, J.L. Santos, K.D. Swenerton, and J.D. Seidman Differences in tumor type in low-stage versus high-stage ovarian carcinomas Int J Gynecol Pathol 29 2010 203 211
6. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, and R. Atkinson Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691 (Pubitemid 39585637)
7. T. Sugiyama, T. Kamura, J. Kigawa, N. Terakawa, Y. Kikuchi, and T. Kita Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 2000 2584 2589 (Pubitemid 30331967)
8. Japanese gynecologic cancer committee Annual report on Japanese gynecologic cancer committee Acta Obstet Gynaecol Jpn 54 2002
9. Japanese gynecologic cancer committee Annual report on Japanese gynecologic cancer committee Acta Obstet Gynaecol Jpn 61 2009
10. H. Itamochi, J. Kigawa, and N. Terakawa Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma Cancer Sci 99 2008 653 658 (Pubitemid 351448066)
11. J.K. Chan, D. Teoh, J.M. Hu, J.Y. Shin, K. Osann, and D.S. Kapp Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers Gynecol Oncol 109 2008 370 376
12. S.F. Serov, R.E. Scully, and L.H. Sobin International histological classification of tumors, November 9 Histologic typing of ovarian tumors 1973 World Health Organization Geneva 1 7
13. F.A. Tavasolli, and P. Devilee World Health Organization classification of tumors Tumors of the breast and the female genital organs 2003 IARC Press, WHO Lyon 8 12
14. Y. Nagai, M. Inamine, and M. Hirakawa Postoperative whole abdominal radiotherapy in clear cell carcinoma of the ovary Gynecol Oncol 107 2007 469 473 (Pubitemid 350160858)
15. Y. Ohishi, Y. Oda, and S. Kuihari Hobnail-like cells in serous borderline tumor do not represent concomittant incipient clear cell neoplasms Hum Pathol 40 2009 1168 1175
16. G. Han, C.H. Gilks, S. Leung, C.A. Ewaniwich, J. Irving, and T.A. Longacre Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases Am J Surg Pathol 32 2008 955 964
17. C.B. Gilks, D.N. Ionescu, S.E. Kalloger, M. Kobel, J. Irving, and B. Clarke Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma Hum Pathol 39 2008 1239 1251
18. K. Yamaguchi, M. Mandai, T. Oura, N. Matsumura, J. Hamanishi, and T. Baba Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic process Oncogene 29 2010 1741 1752
19. M. Kobel, S.E. Kalloger, J. Carrick, D. Huntsman, H. Asad, and E. Oliva A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma Am J Surg Pathol 33 2009 14 21
20. D. DeLair, E. Oliva, M. Kobel, A. Macias, C.B. Gilks, and R.A. Soslow Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases Am J Surg Pathol 35 2011 36 44
21. A. Tsuchiya, M. Sakamoto, and J. Yasuda Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor 1-beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma Am J Pathol 163 2003 2503 2512 (Pubitemid 37466491)
22. M. Kobel, S.E. Kalloger, N. Boyd, S. McKinney, E. Mehl, and C. Palmer Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 2008 e232
23. R. Salani, R.J. Kurman, R. Giuntoli, G. Gardner, R. Bristow, and T.L. Wang Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals higher mutation rate than previously reported and does not correlate with drug resistance Int J Gynecol Cancer 18 2008 487 491 (Pubitemid 351668307)
24. A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, and R. Sharma Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 2010 49 56
25. I. Skirnisdottir, T. Siedal, M.G. Karlsson, and B. Sorbe Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II Int J Oncol 26 2005 177 183
26. K.T. Kuo, T.L. Mao, S. Jones, E. Veras, A. Ayhan, and T.L. Wang Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma Am J Pathol 174 2009 1597 1601
27. M. Kobel, A. Reuss, A. Bois, S. Kommoss, R. Kommoss, and D. Gao The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas J Pathol 222 2010 191.8
28. H.A. Risch, J.R. McLaughin, D.E. Cole, B. Rosen, L. Bradley, and I. Fan Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J Natl Cancer Inst 98 2006 1694 1706 (Pubitemid 44942707)
29. I.G. Campbell, S.E. Russsell, D.Y. Choong, K.G. Montgomery, M.L. Ciavarella, and C.S. Hooi Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 2004 7678 7681 (Pubitemid 39446895)
30. K. Kobayashi, K. Kajiwara, S. Kanayama, Y. Yamada, N. Furukawa, and T. Noguchi Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review) Oncol Rep 22 2009 233 240
31. M. Miyazawa, M. Yasuda, M. Fujita, H. Kajiwara, K. Hirabayashi, and S. Tekekoshi Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma Pathol Int 59 2009 19 27
32. D.S. Tan, M.B. Lambros, S. Rayter, R. Matrajan, R. Vatcheva, and W. Gao PPM1D is a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2009 2269 2280
33. A. Hirasawa, F. Saito-Ohara, J. Inoue, D. Aoki, N. Susumu, and T. Yokoyama Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets Clin Cancer Res 9 2003 1995 2004 (Pubitemid 36687618)
34. X. Lu, B. Nannenga, and L.A. Donehower PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints Genes Dev 19 2005 1162 1174 (Pubitemid 40696183)
35. Y. Suehiro, M. Sakamoto, K. Umayahara, H. Iwabuchi, H. Sakamoto, and N. Tanaka Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas Oncology 59 2000 50 56 (Pubitemid 30435836)
36. Y. Yan, P.T. Cao, P.M. Greer, E.S. Nagengast, R.H. Kolb, and M.C. Mumby Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response Oncogene 29 2010 4317 4374
37. S. Jones, T.L. Wang, M. Shih Ie, T.L. Mao, K. Nakayama, and R. Roden Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
38. M.S. Anglesio, M.S. Care, M. Kobel, H. MacKay, and D.G. Hunstman Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010 Gynecol Oncol 121 2011 407 415
39. K.K. Zorn, T. Bonome, L. Gangi, G.V. Chandramouli, C.S. Awtrey, and G.J. Gardner Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer Clin Cancer Res 11 2005 6422 6430 (Pubitemid 41338978)
40. M. Kobel, H. Xu, P.A. Bourne, B.O. Spaulding, I.M. Shih, and T.L. Mao IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype Mod Pathol 22 2009 469 475
41. Z. Jiang, P.G. Chu, B.A. Woda, K.L. Rock, Q. Liu, and C.C. Hsieh Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study Lancet Oncol 7 2006 556 564 (Pubitemid 43923666)
42. S. Lee, E.I. Garner, W.R. Welch, R.S. Berkowitz, and S.C. Mok Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma Gynecol Oncol 106 2007 311 317 (Pubitemid 47087928)
43. M.P. Stany, V. Vathipadiekal, L. Ozbun, R.L. Stone, S.C. Mok, and H. Xue Identification of novel therapeutic targets in microdissected clear cell ovarian cancers PLoS One 6 e21121 2011 1 13
44. M.S. Anglesio, J. George, H. Kulbe, M. Friedlander, D. Rischin, and C. Lemech IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer Clin Cancer Res 17 2011 2538 2548
45. M. Mandai, N. Matsumura, T. Baba, K. Yamaguchi, J. Hamanushi, and I. Konishi Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype Cancer Lett 310 2011 129 133
46. J.I. Leu, M.A. Crissey, J.P. Leu, G. Ciliberto, and R. Taub Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury Mol Cell Biol 21 2001 414 424 (Pubitemid 32037362)
47. J.A. Rauh-Hain, and R.T. Penson Potential benefit of sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma Int J Gynecol Cancer 18 2008 934 936
48. D. Huang, Y. Ding, Y. Li, W.M. Luo, Z.F. Zhang, and H.L. Wang Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma Cancer Res 70 2010 1053 1062
49. K.C. Wiegand, S.P. Shah, O.M. Al-Agha, Y. Zhao, K. Tse, and T. Zeng ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363 2010 1532 1543
50. D. Reisman, S. Glaros, and E.A. Thompson The SWI/SNF complex and cancer Oncogene 28 2009 1653 1668
51. N.G. Nagl, D.R. Zweitzig, B. Thimmapaya, G.R. Beck, and E. Moran The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest Cancer Res 66 2006 1289 1293 (Pubitemid 43259906)
52. L.R. Duska, L. Garrett, M. Henretta, J.S. Ferris, L. Lee, and N. Horowitz When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared to other epithelial histologic subtypes Gynecol Oncol 116 2010 374 377
53. G.H. Eltabbakh, S.I. Mount, B. Beatty, L. Simmons-Arnold, and K. Cooper Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma J Surg Oncol 93 2006 379 386
54. C.M. Olsen, C.M. Nagle, D.C. Whiteman, D.M. Purdie, A.C. Green, and P.M. Webb Body size and risk of epithelial ovarian and related cancers: a population-based case-control study Int J Cancer 123 2008 450 456 (Pubitemid 351842033)
55. D.M. Purdie, C.J. Bain, P.M. Webb, D.C. Whiteman, S. Pirozzo, and A.C. Green Body size and ovarian cancer: case-control study and systematic review (Australia) Cancer Causes Control 12 2001 855 863 (Pubitemid 33010624)
56. T. Riman, P.W. Dickman, S. Nilsson, H. Nordlinder, C.M. Magnusson, and I.R. Persson Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women Eur J Epidemiol 19 2004 1011 1019 (Pubitemid 40142802)
57. J.B. Greer, F. Modugno, R.B. Ness, and G.O. Allen Anthropometry and the risk of epithelial ovarian cancer Cancer 106 2006 2247 2257 (Pubitemid 43673248)
58. D. Pectasides, E. Pectasides, A. Psyrri, and T. Economopoulos Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11 2006 1089 1094 (Pubitemid 44788400)
59. K. Behbakht, T.C. Randall, and I. Benjamin Clinical characteristics of clear cell carcinoma of the ovary Gynecol Oncol 70 1998 255 258 (Pubitemid 28430939)
60. T. Kishikawa, M. Sakamoto, and Y. Ino Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models Invasion Metastasis 15 1995 11 21
61. M. Kobel, S.E. Kalloger, J.L. Santos, D.G. Hunstman, C.H. Gilks, and K.D. Swenerton Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications Gynecol Oncol 116 2010 50 56
62. A.J. Rauh-Hain, D. Winograd, W.B. Growdon, J.O. Schorge, A.K. Goodman, and D.M. Boruta Prognostic determinants in patients with uterine and ovarian clear cell carcinoma Gynecol Oncol 125 2012 376 380
63. A.W. Kennedy, M. Markman, and C.V. Biscotti Survival probability in ovarian clear cell adenocarcinoma Gynecol Oncol 74 1999 108 114 (Pubitemid 29331176)
64. K. Nishino, Y. Aoki, and T. Amijura Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma Gynecol Oncol 97 2005 893 897 (Pubitemid 40824662)
65. E.L. Jenison, A.H. Montag, and C.T. Griffiths Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma Gynecol Oncol 32 1989 65 71 (Pubitemid 19029870)
66. A.W. Kennedy, C.V. Biscotti, W.R. Hart, and K.D. Webster Ovarian clear cell adenocarcinoma Gynecol Oncol 32 1989 342 349 (Pubitemid 19074926)
67. I.G. Campbell, and E.J. Thomas Endometriosis: candidate genes Hum Reprod Update 7 2001 15 20 (Pubitemid 32111962)
68. A. Aris Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada J Ovarian Res 3 2010 2 7
69. Garrett LA, Growdon WB, Goodman AK, Boruta DM, Schorge JO, del Carmen MG. Endometriosis associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome. J Reprod Med in press.
70. J.P. Orezzoli, A.H. Russell, E. Oliva, M.G. del Carmen, J. Eichorn, and A.F. Fuller Prognostic implication of endometriosis in clear cell carcinoma of the ovary Gynecol Oncol 110 2008 336 344
71. B. Czernobilsky, and W.J. Morris A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes Obstet Gynecol 53 1979 318 323 (Pubitemid 9110954)
72. A. LaGrenade, and S.G. Silverberg Ovarian tumors associated with atypical endometriosis Hum Pathol 19 1988 1080 1084
73. H. Kobayashi, K. Sumimoto, N. Moniwa, M. Imai, K. Takakura, and T. Kuromaki Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan Int J Gynecol Cancer 17 2007 37 43 (Pubitemid 46213967)
74. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
75. M. Kobel, S.E. Kalloger, P.M. Baker, C.A. Ewanowich, J. Arsenaeau, and V. Zherebitskiy Diagnosis of ovarian carcinoma cell type is highly reproducible: a tranCanadian study Am J Pathol 34 2010 984 993
76. S.E. Kalloger, M. Kobel, S. Leung, E. Mehl, D. Gao, and K.M. Marcon Calculator for ovarian carcinoma subtype prediction Mod Pathol 24 2011 512 521
77. M.S. Anglesio, J.M. Arnold, J. Goerge, A.V. Tinker, R. Tothill, and N. Waddell Mutation of ERB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors Mol Cancer Res 6 2008 1678 1690
78. R.W. Tothill, A. Kowalczyk, D. Rischin, A. Bousioutas, I. Haviv, and R.K. van Laar An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin Cancer Res 65 2005 4031 4040 (Pubitemid 40775639)
79. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 11 2010 803 808
80. R. Vang, Ie Shih, and R.J. Kurman Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic, and molecular biologic features and diagnostic problems Adv Anat Pathol 16 2009 267 282
81. M. Takano, Y. Kikuchi, N. Yaeghashi, K. Kuzuya, M. Ueki, and H. Tsuda Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging Br J Cancer 94 2006 1369 1374 (Pubitemid 43772268)
82. C.M. Ho, T.Y. Chien, B.Y. Shih, and S.H. Huang Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement survival in stage I ovarian clear cell carcinoma Gynecol Oncol 88 2003 394 399
83. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary FIGO 6th annual report on the results of treatment in gynecologic cancer Int J Gynecol Obstet 95 Suppl. 1 2006 S161 S192
84. J.C. Aure, K. Hoeg, and P. Kolstad Mesonephroid tumors of the ovary. Clinical and histopathologic studies Obstet Gynecol 37 1971 860 867
85. H.J. Norris, and M. Robinowitz Ovarian adenocarcinoma of mesonephric type Cancer 28 1971 1074 1081
86. G.A. Omura, M.F. Brady, and H.D. Homsley Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience J Clin Oncol 9 1991 1138 1150
87. A.P. Makar, M. Baekelandt, and C.G. Troppe The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer Gynecol Oncol 56 1995 175 180
88. D. Pectasides, G. Fountzilas, G. Aravantinos, C. Kalofonos, H. Esftathiou, and D. Farmakis Advanced stage clear-cell ovarian cancer: the Hellenic cooperative oncology group experience Gynecol Oncol. 102 2006 285 291 (Pubitemid 44041640)
89. I. Gorai, T. Nakazawa, and E. Miyagi Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties Gynecol Oncol 57 1995 33 46
90. P.A. Andrews, S. Velury, and S.C. Mann Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells Cancer Res 48 1988 68 73 (Pubitemid 18030332)
91. K. Kasahara, Y. Fujiwara, and K. Nishio Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin Cancer Res 51 1991 3237 3242
92. J. Kigawa, Y. Minagawa, and X. Cheng Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer Clin Cancer Res 4 1998 1737 1741 (Pubitemid 28304736)
93. H. Itamochi, J. Kgawa, and R. Akeshima Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary Oncology 62 2002 349 353 (Pubitemid 34914104)
94. H. Itamichi, J. Kigawa, and T. Sugiyama Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary Obstet Gynecol 100 2002 281 287 (Pubitemid 34874791)
95. S. Suzuki, H. Kajiyama, K. Shibata, K. Ino, A. Nawa, and K. Sakakibara Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol 19 2008 1284 1287 (Pubitemid 351911958)
96. M. Takano, T. Sugiyama, N. Yaegashi, M. Suziki, H. Tsuda, and S. Sagae The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study Int J Gynecol Cancer 19 2009 1353 1357
97. P.J. Timmers, A.H. Zwinderman, I. Teodorovic, I. Vergote, and J.B. Trimbos Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in large randomized trial Int J Gynecol Cancer 19 2009 88 93
98. I. Vergote, J. De Brabanter, A. Fyles, K. Bertelsen, N. Einhorn, and P. Sevelda Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma Lancet 357 2001 176 182 (Pubitemid 32108089)
99. T. Satoh, M. Hate, Y. Watanabe, N. Yaegashi, O. Ishioko, and S. Kodama Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection J Clin Oncol 28 2010 1727 1732
100. J.B. Trimbos, M. Parmar, I. Vergote, D. Guthrie, G. Bolis, and N. Colombo International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma J Natl Cancer Inst 95 2003 105 112 (Pubitemid 36196730)
101. J.Y. Park, D.Y. Kim, D.H. Suh, Y.M. Kim, and J.H. Nam Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes Gynecol Oncol 110 2008 345 353
102. S. Pather, and M.A. Quinn Clear-cell cancer of the ovary - is it chemosensitive? Int J Gynecol Cancer 15 2005 432 437 (Pubitemid 40705537)
103. M. Takano, T. Sugiyama, N. Yaegashi, M. Sakuma, M. Sizuki, and Y. Saga Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study Int J Gynecol Cancer 18 2008 937 942
104. R.F. Ozols, B.N. Bundy, B.E. Greet, J.M. Fowler, D. Clarck-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
105. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
106. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial Lancet 360 2002 505 515
107. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
108. P.G. Rose, S. Nerenstone, M.F. Brady, D. Clarke-Pearson, G. Olt, and S.C. Rubin Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
109. GOG 182-ICON 5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D) or topotecan (T) in patients with advanced-stage Oncol 24 2006 5002 5012
110. A. du Bois, B. Weber, J. Rochon, W. Meier, A. Goupil, and S. Olbricht Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigaterus Nationaux pour l'Etude de Cancers Ovariens J Clin Oncol 24 2006 1127 1135 (Pubitemid 46638810)
111. J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. du Bois, and U. Wagner Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 2006 1036 1045 (Pubitemid 44288151)
112. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E.M. Avail-Lundqvist, and M. Bookman Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12 (Pubitemid 41631227)
113. E.L. Trimble, and B.M. Fja Recommendations of the 2005 Ovarian Cancer State of the Science Meeting Gynecol Oncol 103 2006
114. T.K.C. Enomoto, M. Yamasaki, M. Kuragaki, Y. Sagita, H. Otsuki, and N. Ikegami Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22 2003 1797 [Abstract:447]
115. C.M. Ho, Y.J. Huang, T.C. Chen, S.H. Huang, F.S. Liu, and C.C. Chan Chien Pure-type clear cell carcinoma of the ovary as a distinct histologic type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease Gynecol Oncol 94 2004 197 203
116. H. Utsunomiya, J. Akahira, S. Tanno, T. Moriya, M. Toyoshima, and H. Niikura Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial Int J Gynecol Cancer 16 2006 52 56
117. F.O. Recio, M.S. Piver, R.E. Hempling, and D.L. Driscoll Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy Cancer 78 1996 2157 2163 (Pubitemid 26367609)
118. M. Nishida Chemosensitivity of ovarian clear cell carcinoma in vitro Oncol Chemother 8 1992 128 136
119. I. Ohta, I. Gorai, Y. Miyamoto, J. Yang, J.H. Zheng, and N. Kawata Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells Cancer Lett 162 2001 39 48
120. E. Reed, J.J. Yu, A. Davies, J. Gannon, and S.L. Armentrout Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer Clin Cancer Res 14 2003 5230 5299
121. S. Adachi, T. Ogasawara, N. Yamasaki, H. Shibahara, R. Kanazawa, and Y. Tsuji A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma J Clin Oncol 29 1999 434 437
122. Y. Shimizu, S. Umezawa, and K. Hasumi A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma Ann Acad Med Singapore 27 1998 650 656 (Pubitemid 29037230)
123. T. Tanaka, N. Umesaki, and S. Ogita Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases Eur J Gynaecol Oncol 21 2000 377 379
124. M. Nishida, H. Tsunoda, Y. Ichikawa, and H. Yoshikawa Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma Int J Clin Oncol 9 2004 403 405 (Pubitemid 40012711)
125. S. Takakura, M. Takano, F. Takahashi, T. Saito, D. Aoki, and N. Inaba Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary. A JGOG study Int J Gynecol Cancer 20 2010 240 247
126. A.J. Dembo, R.S. Bush, F.A. Beale, H.A. Bean, J.F. Pringle, and J. Sturgeon Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with completed pelvic operation Am J Obstet Gynecol 134 1979 793 800 (Pubitemid 9187951)
127. B. Sorbe Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment Int J Gynecol Cancer 13 2003 278 286 (Pubitemid 38222574)
128. J.A. Ledermann, A.J. Dembo, J.F. Sturgeon, S. Fine, R.S. Bush, and A.W. Fyles Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation Gynecol Oncol 41 1991 30 35
129. D. Gelblum, A. Mychalczak, L. Almadrones, D. Spriggs, and R. Barakat Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma Gynecol Oncol 69 1998 36 41 (Pubitemid 28201669)
130. Y. Nagai, M. Inamine, M. Hirakawa, K. Kamiyama, K. Ogawa, and T. Toita Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary Gynecol Oncol 107 2007 469 473 (Pubitemid 350160858)
131. K.D. Swenerton, J.L. Santos, C.B. Gilks, M. Kobel, P.J. Hoskins, and F. Wong Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers Ann Oncol 22 2011 341 347
132. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, and J. Verweij Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
133. R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, and O. Rixe Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
134. D.B. Mendel, A.D. Larid, X. Xi, S.G. Louise, J.G. Chistensen, and G. Li In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337 (Pubitemid 36109749)
135. R. Kumar, M.C. Crouthamel, D.H. Rominger, R.R. Gontarek, P.L. Tummino, and R.A. Levin Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer 101 2009 1717 1723
136. Y. Kikuchi, K. Kudoh, M. Talano, R. Kikuchi, T. Kita, and Y. Hamada Effect of treatment by temsirolimus on patients with clear cell carcinoma of the ovary J Clin Oncol 28 2010 [Abstract 5086]
137. Y.Y. Lee, T.J. Kim, M.J. Kim, H.J. Kim, T. Song, and M.K. Kim Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis Gynecol Oncol 122 2011 541 547